- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
MK-8776 (SCH 900776)是一種選擇性Chk1抑制劑,無細胞試驗中IC50為3 nM,比作用于Chk2選擇性高500倍。Phase 2。
MK-8776 (SCH 900776) Chemical Structure
CAS: 891494-63-6
相關(guān)靶點 | Chk1 Chk2 | 點擊展開 |
---|---|---|
相關(guān)產(chǎn)品 | AZD7762 Rabusertib (LY2603618) CHIR-124 Prexasertib HCl (LY2606368) PF-477736 BML-277 (Chk2 Inhibitor II) Prexasertib (LY2606368) CCT245737 (SRA737) GDC-0575 | 點擊展開 |
相關(guān)化合物庫 | 激酶抑制劑庫 PI3K/Akt 抑制劑庫 MAPK抑制劑庫 DNA損傷/ DNA修復化合物庫 細胞周期化合物庫 | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
U2OS | Function Assay | 1 μM | 24 h | abrogates of cell cycle arrest? | 22510560 |
HCT116 | Function Assay | 1 μM | 24 h | abrogates of cell cycle arrest? | 22510560 |
ML-1 | Apoptosis Assay | 25/50/100 nM | 24 h | enhances cytarabine-induced apoptosis | 22869869 |
HL-60 | Apoptosis Assay | 30/100/300 nM | 24 h | enhances cytarabine-induced apoptosis | 22869869 |
U937 | Function Assay | 100-500 nM | 4 h? | induces increased phosphorylation of H2AX | 22869869 |
U937 | Function Assay | 100 nM | 4 h? | reverses the cytarabine-induced inhibition of?3H-thymidine incorporation into DNA | 22869869 |
U937 | Function Assay | 100-500 nM | 4 h? | decreases the cytarabine-induced Chk1 autophosphorylation at Ser296?and prevents Cdc25A downregulation | 22869869 |
U2OS? | Growth Inhibition Assay | 0-10 μM | 24/48 h | inhibits cell growth dose dependently | 22937147 |
HMEC | Cell Viability Assay | 500 nM | 72 h | results in G1/S-phase accumulation combined with MK-1775 | 23148684 |
HRE | Cell Viability Assay | 500 nM | 72 h | results in G1/S-phase accumulation combined with MK-1775 | 23148684 |
Su.86.86 | Cell Viability Assay | 500 nM | 72 h | results in G1/S-phase accumulation combined with MK-1775 | 23148684 |
H2009 | Cell Viability Assay | 500 nM | 72 h | results in G1/S-phase accumulation combined with MK-1775 | 23148684 |
HCC2998 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
U20S | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
A498 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
TK10 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
AsPC-1 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
H23 | Growth Inhibition Assay | 500 nM | 24 h | enhances the chemosensitization to PMX | 24113549 |
H1437 | Growth Inhibition Assay | 500 nM | 24 h | enhances the chemosensitization to PMX | 24113549 |
H1993 | Growth Inhibition Assay | 500 nM | 24 h | enhances the chemosensitization to PMX | 24113549 |
H1299 | Growth Inhibition Assay | 500 nM | 24 h | enhances the chemosensitization to PMX | 24113549 |
MiaPaCa-2 | Growth Inhibition Assay | 10-1000 nM | 24-48h | enhances the chemosensitization to | 23804422 |
BxPC-3 | Growth Inhibition Assay | 10-1000 nM | 24-48h | enhances the chemosensitization to | 23804422 |
U2OS? | Function Assay | 2 μM | 0-24 h | induces phosphorylation of Chk1 at serine 345 at both concentrations as early as 2 h after administration | 22937147 |
A2058? | Cell Viability Assay | 37.5-300 nM | 72 h | reduces the MK-1775 EC50?by 5-fold to an average of 45 nM | 23148684 |
MOLM-13? | Apoptosis Assay | 100-700 nM | 48 h | induces apoptosis dose dependently | 23536721 |
U937 | Apoptosis Assay | 100-700 nM | 48 h | induces apoptosis dose dependently | 23536721 |
MV-4-11 | Apoptosis Assay | 100-700 nM | 48 h | induces apoptosis dose dependently | 23536721 |
OVCAR-8 | Growth Inhibition Assay | 0.3 μM | 8 d | sensitizes the cell lines to | 23548269 |
U251 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
HCT115 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
SW620 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
IGROV-1 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
HCT116 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
MCF10A | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
MiaPaCa-2 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
MDA-MB-231 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
U87 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
MDA-MB-435 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
SNB19 | Growth Inhibition Assay | 200/2000 nM | 24 h | decreases the IC50 of | 24359526 |
AsPC-1 | Growth Inhibition Assay | 10-1000 nM | 24-48h | enhances the chemosensitization to | 23804422 |
SKOV3 | Growth Inhibition Assay | 0.3 μM | 8 d | sensitizes the cell lines to | 23548269 |
Sf9 | Function assay | Inhibition of recombinant CDK2/Cyclin A expressed in insect Sf9 cells assessed as inhibition of [33P]-ATP incorporation into biotinylated histone H1 after 1 hr by liquid scintillation counting, IC50 = 0.16 μM. | 21094607 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | MK-8776 (SCH 900776)是一種選擇性Chk1抑制劑,無細胞試驗中IC50為3 nM,比作用于Chk2選擇性高500倍。Phase 2。 | ||||
---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | SCH 900776是Chk2和CDK2的低效抑制劑,IC50分別為1.5 μM 和 0.16 μM。SCH 900776對細胞色素P450人肝微粒體亞型1A2,2C9,2C19,2D6,和3A4沒有顯著的抑制作用。羥基脲下暴露24小時后,SCH 900776誘導DNA復制能力劑量依賴性損失。SCH 900776增強γ-H2AX對羥基脲,5-氟尿嘧啶,和阿糖孢苷的響應。與抗代謝物結(jié)合,SCH 900776在2小時內(nèi)誘導γ-H2AX的累積,表明復制叉瓦解,并且雙鏈DNA斷裂。此外,SCH 900776以劑量依賴的方式抑制Chk1 pS296自磷酸化的積累。增殖的WS1細胞暴露于SCH 900776,與Chk1 pS345快速的,劑量依賴性聚集相關(guān),表明正常細胞的循環(huán)群誘導Chk1 pS345在暴露于SCH 900776后,是一部分無效循環(huán),這也許通過AT-家族激酶和DNA-PK驅(qū)動。[1] |
|||
---|---|---|---|---|
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | Cyclin E / pY15-CDK / γH2AX p-chk1(ser345) / CDC25A | 26595527 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | 遞增劑量的SCH 900776 (16 mg/kg和32 mg/kg)誘導腫瘤響應持續(xù)改進。重要的是,在BALB/c 小鼠體內(nèi),SCH 900776的劑量與強的生物標志物活化相關(guān),而提高的腫瘤響應對血液學指標增強的毒性無關(guān)。[1] |
|
---|---|---|
動物實驗 | Animal Models | 皮下注射A2780 或 MiaPaCa2細胞的額雌性裸鼠 |
Dosages | ~50 mg/kg | |
Administration | 腹腔內(nèi)注射 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT00779584 | Completed | Hodgkin Disease|Lymphoma Non-Hodgkin|Neoplasms |
Merck Sharp & Dohme LLC |
October 17 2008 | Phase 1 |
分子量 | 376.25 | 分子式 | C15H18BrN7 |
CAS號 | 891494-63-6 | SDF | Download MK-8776 (SCH 900776) SDF |
Smiles | CN1C=C(C=N1)C2=C3N=C(C(=C(N3N=C2)N)Br)C4CCCNC4 | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 75 mg/mL ( (199.33 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項
問題 1:
I would like to know whether your product S2735 is the optically pure R enantiomer or whether it is a racemic mix.
回答:
Our S2735 MK-8776 (SCH 900776) is R enantiomer.